Adjuvant nivolumab benefit in urothelial carcinoma sustained with longer follow-upMay 14th 2022
Adjuvant nivolumab continued to demonstrate a clinically meaningful disease-free survival benefit in patients with high-risk, muscle-invasive urothelial carcinoma, according to extended follow-up from the phase 3 CheckMate 274 trial.
Dr. Petrylak highlights the latest advances in metastatic urothelial cancerMarch 22nd 2022
In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.
PSMA-targeted therapy shows early promise in locally advanced prostate cancerSeptember 11th 2021
Now that pivotal trials have demonstrated a survival benefit with PSMA-targeted therapy in metastatic prostate cancer, researchers are hoping to deliver the exciting new approach earlier in the disease course.